Efficacy of a 12-week simeprevir plus peginterferon/ribavirin (PR) regimen in treatment-naïve patients with hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment virologic response

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Asselah, Tarik ^a   Moreno, Christophe ^b   Sarrazin, Christoph ^c   Gschwantler, Michael ^d   Foster, Graham R ^e   Craxi, Antonio ^f   Buggisch, Peter ^g   Sanai, Faisal ^h   Bicer, Ceyhun ⁱ   Lenz, Oliver ⁱ   Van Dooren, Gino ⁱ   Nalpas, Catherine ^j   Lonjon Domanec, Isabelle ^j   Schlag, Michael ^k   Buti, Maria ^l  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d WILHELMINEN HOSPITAL   (Austria)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF PALERMO   (Italy)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j Janssen Pharmaceuticals   (France)

^k Janssen Cilag Pharma GmbH   (Austria)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; SIMEPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; ASTHENIA; DECREASED APPETITE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRURITUS; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; METABOLISM; MIDDLE AGED; PATHOGENICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SIMEPREVIR; VIRAL LOAD; YOUNG ADULT;

EID: 85008881503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168713     Document Type: Article

References (60)

1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. September 2016. Available at: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf [last accessed 22 November 2016].
2. Shiffman ML, Long AG, James A, Alexander P. My treatment approach to chronic hepatitis C virus. Mayo Clin Proc. 2014; 89:934-42. doi: 10.1016/j.mayocp.2014.04.013 PMID: 24867397
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59:318-27. doi: 10.1002/hep.26744 PMID: 24115039
4. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Vir Hepat. 2013; 20:669-77.
5. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol. 2011; 54:1250-62. doi: 10.1016/j.jhep.2010.11.016 PMID: 21316497
6. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61:S45-57. doi: 10.1016/j.jhep.2014.07.027PMID: 25086286
7. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87. doi: 10.1002/hep.27259 PMID: 25069599
8. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011; 31:S45-52.
9. Asselah T, De Muynck S, Broë t P, Masliah-Planchon J, Blanluet M, Bièche I, et al. IL28B polymorphism is associated with treatment response in chronic hepatitis C. J Hepatol. 2012; 56:527-32. PMID: 21951981
10. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010; 30:342-55. doi: 10.1111/j.1478-3231.2009.02188.x PMID: 20015149
11. Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016; 1:25-35.
12. Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016; 1:36-44.
13. Hinrichsen H, Wedemeyer H, Christensen S, Sarrazin CM, Baumgarten A, Mauss S, et al. Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry. J Hepatol 2016 64(Suppl 1):S159.
14. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarȩbska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir - dasabuvir - ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016; 44:946-56. PMID: 27611776
15. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385:2502-9. doi: 10.1016/S0140-6736(15)60159-3 PMID: 25837829
16. El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir in Egyptian patients with chronic hepatitis C: a real-world experience. Gut 2016; ePub ahead of print.
17. Kwo P, Gane E, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection. Gastroenterology 2016; ePub ahead of print.
18. Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with Hepatitis C Genotype 4 Infection. Hepatology 2016; 64:1049-56. doi: 10.1002/hep.28706 PMID: 27351341
19. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2016; 373:2599-607.
20. Gane EJ, Kowdley KV, Pound D, Stedman CAM, Davis M, Etzkom K, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Openlabel, Phase 2 Trial. Gastroenterology 2016; ePub ahead of print.
21. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology 2016; ePub ahead of print.
22. Zhong M, Peng E, Huang N, Huang Q, Huq A, Lau M, et al. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. Bioorg Med Chem Lett 2016; 26:4508-12. doi: 10.1016/j.bmcl.2016.07.066 PMID: 27506559
23. Esmat G, El Raziky M, Elbaz T, Abouelkhair MM, Gamal El Deen H, Ashour MK, et al. High virologic response rate in Egyptian HCV Genotype 4 patients treated with Ravidasvir (PPI-668) and sofosbuvir: results of a large multicenter Phase 3 registrational trial. AASLD 2015. Abstract LB-4.
24. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med. 2014; 370:1552-3. doi: 10.1056/NEJMe1401508 PMID: 24725236
25. MapCrowd. Dying at these prices: Generic HCV cure denied. July 2016. Available at: http://www.mapcrowd.org/public/pdf/EN-mapCrowd-Report2.pdf [Last accessed 22 November 2016].
26. Omata M, Kanda T, Wei L, Yu M-L, Chuang W- L, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016; 10:702-26. doi: 10.1007/s12072-016- 9717-6 PMID: 27130427
27. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35:704-8. doi: 10.1053/jhep.2002.31311 PMID: 11870387
28. Jansen-Cilag. OLYSIO (simeprevir) tablets. Summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002777/WC500167867.pdf [last accessed 22 November 2016].
29. Janssen Therapeutics. OLYSIO (simeprevir) tablets. Prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205123s001lbl.pdf [last accessed 22 November2016].
30. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, et al. Efficacy and safety of simeprevir with peg-IFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015; 62:1047-55. doi: 10.1016/j.jhep.2014.12.031 PMID: 25596313
31. Nelson DR, Poordad F, Feld JJ, Fried MW, Jacobson IM, Pockros PJ, et al. High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naïves and prior relapsers with G1 chronic hepatitis C: concise interim analysis. J Hepatol. 2013; 58:S362.
32. Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxõâ A, et al. An open label trial of 12- week simeprevir plus pegylated interferon/ribavirin in treatment-naïve patients with HCV genotype 1. PLoS ONE 2016 [in press].
33. American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing and treating hepatitis C. 2015. Available at: http://www.hcvguidelines.org/full-report-view[last accessed 22 November 2016].
34. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24:289-93. doi: 10.1002/hep.510240201 PMID: 8690394
35. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349:825-32. PMID: 9121257
36. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011; 5:625-34. doi: 10.1007/s12072-010-9240-0 PMID: 21484142
37. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Lissandrin R, Filice G, et al. Performance of liver stiffness measurements by transient elastography in chronic hepatitis. World J Gastroenterol. 2013; 7:49-56.
38. Huwart L, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007; 245:458-66. doi: 10.1148/radiol.2452061673 PMID: 17940304
39. Manns M, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, et al. Simeprevir with peginterferon/ ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from phase IIb and IIII studies. J Viral Hep. 2015; 22:366-75.
40. Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis 2016; e196-201. doi: 10.1016/S1473-3099(16)30005-6 PMID: 27421993
41. Andrieux-Meyer I, Cohn J, Affonso de Araújo ES, Hamid SS. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 2015; 3:e676-7. doi: 10.1016/S2214-109X(15)00156-4 PMID: 26475012
42. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Medicine 2016; 13: e1002032. doi: 10.1371/journal.pmed.1002032 PMID: 27243629
43. Drugs for Neglected Diseases Initiative (DNDI). An alternative research and development strategy to deliver affordable treatments for Hepatitis C patients. April 2016. Available at: http://www.dndi.org/wpcontent/uploads/2016/04/AlternativeRDStrategyHepC.pdf [Last accessed 22 November 2016].
44. Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence? The case of Greece. J Gastroenterol Hepatol 2016; ePub ahead of print.
45. Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Rev Gastroenterol Hepatol 2016; ePub ahead of print.
46. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011; 33:1268-80. doi: 10.1016/j.clinthera.2011.07.008 PMID: 21840056
47. Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, et al. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Vir Hepat 2016; 23:767-79.
48. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of early treatment of Hepatitis C Virus Genotype 1 by stage of liver fibrosis in a US treatment-naïve population. JAMA Intern Med 2016; 176:65-73. doi: 10.1001/jamainternmed.2015.6011 PMID: 26595724
49. Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA, et al. Cost-effectiveness model for hepatitis C screening and treatment: implications for Egypt and other countries with high prevalence. Glob Public Health. 2015; 10:296-317. doi: 10.1080/17441692.2014.984742 PMID: 25469976
50. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with hepatitis C in Japan. Ann Intern Med 1999; 131:174-81. PMID: 10428733
51. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61:1860-9. doi: 10.1002/hep.27736 PMID: 25677072
52. Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepat Med. 2016 Mar 4; 8:21-6.
53. Woode ME, Abu-Zaineh M, Perriëns J, Renaud F, Wiktor S, Moatti J-P. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Vir Hepat 2016; 23:522-34.
54. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87. doi: 10.1056/NEJMoa1214853 PMID: 23607594
55. Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015; 63:581-5. doi: 10.1016/j.jhep.2015.04.023 PMID: 25937436
56. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. J Hepatol 2015;62:1040-6. doi: 10.1016/j.jhep.2014.10.044 PMID: 25450208
57. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384:403-13. doi: 10.1016/S0140-6736(14)60494-3 PMID: 24907225
58. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384:414-26. doi: 10.1016/S0140-6736(14)60538-9 PMID: 24907224
59. Al-Ashgar HI, Khan MQ, Helmy A, Al-Thawadi S, Al-Ahdal MN, Khalaf N, et al. Relationship of interferon- γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol. 2013; 25:404-10. doi: 10.1097/MEG.0b013e32835bc2cf PMID: 23470264
60. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17:687-94. PMID: 12641518